Texas has reached consecutive College Football Playoff semifinals and posted 25 wins over two years. You have to go all the ...
Members of a working group examining the city's pre-hospitilization services say they've received reports of delays in fire ...
Team Gleason has expanded its collaboration with Stentrode developer Synchron to help teach people about brain-computer ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...
Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...